EP3071198 - TREATMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA [Right-click to bookmark this link] | Status | The application has been withdrawn Status updated on 12.01.2018 Database last updated on 11.11.2024 | Most recent event Tooltip | 12.01.2018 | Withdrawal of application | published on 14.02.2018 [2018/07] | Applicant(s) | For all designated states Cymabay Therapeutics, Inc. 7999 Gateway Blvd, Suite 130 Newark, CA 94560 / US | [2016/39] | Inventor(s) | 01 /
MARTIN, Robert L. 7999 Gateway Blvd. Suite 130 Newark, CA 94560 / US | 02 /
MCWHERTER, Charles A. 7999 Gateway Blvd. Suite 130 Newark, CA 94560 / US | 03 /
O'MARA, Patrick J. 7999 Gateway Blvd. Suite 130 Newark, CA 94560 / US | [2016/39] | Representative(s) | Wills, Andrew Jonathan, et al Mewburn Ellis LLP City Tower 40 Basinghall Street London EC2V 5DE / GB | [2016/39] | Application number, filing date | 14809184.6 | 14.11.2014 | [2016/39] | WO2014US65742 | Priority number, date | US201361906837P | 20.11.2013 Original published format: US 201361906837 P | US201461942438P | 20.02.2014 Original published format: US 201461942438 P | US201461942941P | 21.02.2014 Original published format: US 201461942941 P | US201461974816P | 03.04.2014 Original published format: US 201461974816 P | US201461974785P | 03.04.2014 Original published format: US 201461974785 P | US201461974725P | 03.04.2014 Original published format: US 201461974725 P | [2016/39] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2015077154 | Date: | 28.05.2015 | Language: | EN | [2015/21] | Type: | A1 Application with search report | No.: | EP3071198 | Date: | 28.09.2016 | Language: | EN | The application published by WIPO in one of the EPO official languages on 28.05.2015 takes the place of the publication of the European patent application. | [2016/39] | Search report(s) | International search report - published on: | EP | 28.05.2015 | Classification | IPC: | A61K31/192, A61K31/4468, A61K31/7088, A61P3/06, A61K39/395 | [2016/39] | CPC: |
A61K31/192 (EP,KR,US);
A61K31/4468 (EP,KR,US);
A61K31/7088 (KR);
A61K39/3955 (EP,KR,US);
A61P3/06 (EP,KR);
A61P3/10 (EP,KR);
A61P43/00 (EP,KR);
A61P9/00 (EP);
A61P9/10 (EP,KR);
C07K16/40 (EP,KR,US);
C12N15/113 (KR,US);
A61K2300/00 (KR);
| C-Set: |
A61K31/192, A61K2300/00 (EP,US);
A61K31/4468, A61K2300/00 (US,EP);
A61K31/7088, A61K2300/00 (US,EP);
A61K39/3955, A61K2300/00 (US,EP) | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2016/39] | Title | German: | BEHANDLUNG VON HOMOZYGOTER FAMILIÄRER HYPERCHOLESTERINÄMIE | [2016/39] | English: | TREATMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | [2016/39] | French: | TRAITEMENT DE L'HYPERCHOLESTÉROLÉMIE FAMILIALE HOMOZYGOTE | [2016/39] | Entry into regional phase | 07.06.2016 | National basic fee paid | 07.06.2016 | Designation fee(s) paid | 07.06.2016 | Examination fee paid | Examination procedure | 07.06.2016 | Examination requested [2016/39] | 23.02.2017 | Amendment by applicant (claims and/or description) | 08.01.2018 | Application withdrawn by applicant [2018/07] | Fees paid | Renewal fee | 10.11.2016 | Renewal fee patent year 03 | 13.11.2017 | Renewal fee patent year 04 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XDYI]US2010152295 (KARPF DAVID [US], et al); | [Y]WO2012154999 (AMGEN INC [US], et al); | by applicant | US5712279 | US5739135 | US5883109 | US6066653 | US7301050 | US7407943 | US7635718 | US7709682 | US2010152295 | US7932268 | US8106095 |